scholarly journals Association between Artificial Light at Night Exposure and breast and prostate cancer risk – the review

2021 ◽  
Vol 11 (8) ◽  
pp. 148-160
Author(s):  
Marlena Zając ◽  
Konrad Warchoł ◽  
Monika Borowiecka ◽  
Agnieszka Brzezińska
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Biological Clock ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Artificial Light ◽  
Light At Night ◽  
Exposure Levels ◽  
Breast And Prostate Cancer ◽  
Risk Of Cancer

Introduction and purpose: Light is one of the defining features of life on the Earth, allowing certain biological processes to be subordinated to its presence and absence. With the introduction of artificial light, the human natural biological clock was dysregulated. Apart from that, the studies showed a connection between exposure to artificial light at night (ALAN) and carcinogenesis. The aim of this review was to present currently available knowledge in the online database PubMed about Association Between Artificial Light at Night and Breast and Prostate Cancer Risk Brief description of the state of knowledge: The article covers clinical and population-based control studies which indicate to ALAN exposure can lead to increased incidence of breast and prostate cancer by disruption of circadian rhythms in several mechanisms involving suppression of melatonin production, dysregulation of sleep–activity pattern and disruption of circadian genes. Conclusions: The review support an assumption that breast and prostate cancer incidence is a consequence of ALAN exposure. Further studies should clarify the relationship between ALAN exposure and other types of cancer. Besides, ALAN exposure levels should be measured more precisely than by satellite pictures analysis to reliably conduct studies proving the relation between ALAN exposure and risk of cancer development.

scholarly journals Evaluating the Association between Artificial Light-at-Night Exposure and Breast and Prostate Cancer Risk in Spain (MCC-Spain Study)

2018 ◽  
Vol 126 (4) ◽  
pp. 047011 ◽  
Author(s):  
Ariadna Garcia-Saenz ◽  
Alejandro Sánchez de Miguel ◽  
Ana Espinosa ◽  
Antonia Valentin ◽  
Núria Aragonés ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Artificial Light ◽  
Light At Night ◽  
Breast And Prostate Cancer

Exposure to Artificial Light-at-Night and Breast and Prostate Cancer Risk in Spain (MCC-Spain study)

2018 ◽  
Vol 2017 (1) ◽  
pp. 523
Author(s):  
Manolis Kogevinas ◽  
Ariadna Garcia-Saenz ◽  
Alejandro Sánchez de Miguel ◽  
Marina Pollán ◽  
Javier Llorca ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Artificial Light ◽  
Light At Night ◽  
Breast And Prostate Cancer

scholarly journals The Association of Nighttime Fasting Duration and Prostate Cancer Risk: Results from the Multicase-Control (MCC) Study in Spain

Nutrients ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 2662
Author(s):  
Anna Palomar-Cros ◽  
Ana Espinosa ◽  
Kurt Straif ◽  
Beatriz Pérez-Gómez ◽  
Kyriaki Papantoniou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Lower Risk ◽  
Night Shift ◽  
Prostate Cancer Risk ◽  
Meal Timing ◽  
Risk Of Cancer ◽  
Fasting Duration ◽  
Population Controls ◽  
Reduced Risk

Nighttime fasting has been inconclusively associated with a reduced risk of cancer. The purpose of this study was to investigate this association in relation to prostate cancer risk. We examined data from 607 prostate cancer cases and 848 population controls who had never worked in night shift work from the Spanish multicase-control (MCC) study, 2008–2013. Through an interview, we collected circadian information on meal timing at mid-age. We estimated odds ratios (OR) and 95% confidence intervals (CI) with unconditional logistic regression. After controlling for time of breakfast, fasting for more than 11 h overnight (the median duration among controls) was associated with a reduced risk of prostate cancer compared to those fasting for 11 h or less (OR = 0.77, 95% 0.54–1.07). Combining a long nighttime fasting and an early breakfast was associated with a lower risk of prostate cancer compared to a short nighttime fasting and a late breakfast (OR = 0.54, 95% CI 0.27–1.04). This study suggests that a prolonged nighttime fasting duration and an early breakfast may be associated with a lower risk of prostate cancer. Findings should be interpreted cautiously and add to growing evidence on the importance of chrononutrition in relation to cancer risk.

Adherence to Mediterranean diet and prostate cancer risk in Sicily: population-based case–control study

2018 ◽  
Vol 31 (4) ◽  
pp. 269-275 ◽  
Author(s):  
Giorgio Ivan Russo ◽  
Tatiana Solinas ◽  
Daniele Urzì ◽  
Salvatore Privitera ◽  
Daniele Campisi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Mediterranean Diet ◽  
Case Control Study ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Case Control ◽  
Control Study

A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk

2014 ◽  
Vol 65 (1) ◽  
pp. 169-176 ◽  
Author(s):  
Robert Karlsson ◽  
Markus Aly ◽  
Mark Clements ◽  
Lilly Zheng ◽  
Jan Adolfsson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Population Based

Prostate cancer risk among users of finasteride and alpha-blockers – A population based case–control study

2007 ◽  
Vol 43 (4) ◽  
pp. 775-781 ◽  
Author(s):  
Teemu J. Murtola ◽  
Teuvo L.J. Tammela ◽  
Liisa Määttänen ◽  
Matti Hakama ◽  
Anssi Auvinen
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Case Control ◽  
Alpha Blockers ◽  
Control Study

Prostate cancer risk calculators for healthy population: A systematic review (Preprint)

2021 ◽  
Author(s):  
Antonio Bandala-Jacques ◽  
Kevin Daniel Castellanos Esquivel ◽  
Fernanda Pérez-Hurtado ◽  
Cristobal Hernández-Silva ◽  
Nancy Reynoso-Noverón
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Systematic Review ◽  
Cancer Risk ◽  
Digital Rectal Examination ◽  
Prostate Cancer Risk ◽  
Individual Risk ◽  
Healthy Population ◽  
Risk Of Cancer ◽  
The Impact

BACKGROUND Screening for prostate cancer has long been a debated, complex topic. The use of risk calculators for prostate cancer is recommended for determining patients’ individual risk of cancer and the subsequent need for a prostate biopsy. These tools could lead to a better discrimination of patients in need of invasive diagnostic procedures and for optimized allocation of healthcare resources OBJECTIVE To systematically review available literature on current prostate cancer risk calculators’ performance in healthy population, by comparing the impact factor of individual items on different cohorts, and the models’ overall performance. METHODS We performed a systematic review of available prostate cancer risk calculators targeted at healthy population. We included studies published from January 2000 to March 2021 in English, Spanish, French, Portuguese or German. Two reviewers independently decided for or against inclusion based on abstracts. A third reviewer intervened in case of disagreements. From the selected titles, we extracted information regarding the purpose of the manuscript, the analyzed calculators, the population for which it was calibrated, the included risk factors, and the model’s overall accuracy. RESULTS We included a total of 18 calculators across 53 different manuscripts. The most commonly analyzed ones were they PCPT and ERSPC risk calculators, developed from North American and European cohorts, respectively. Both calculators provided high precision for the diagnosis of aggressive prostate cancer (AUC as high as 0.798 for PCPT and 0.91 for ERSPC). We found 9 calculators developed from scratch for specific populations, which reached diagnostic precisions as high as 0.938. The most commonly included risk factors in the calculators were age, PSA levels and digital rectal examination findings. Additional calculators included race and detailed personal and family history CONCLUSIONS Both the PCPR and the ERSPC risk calculators have been successfully adapted for cohorts other than the ones they were originally created for with no loss of diagnostic accuracy. Furthermore, designing calculators from scratch considering each population’s sociocultural differences has resulted in risk tools that can be well adapted to be valid in more patients. The best risk calculator for prostate cancer will be that which was has been calibrated for its intended population and can be easily reproduced and implemented CLINICALTRIAL CRD42021242110

scholarly journals Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

2017 ◽  
Vol 35 (20) ◽  
pp. 2240-2250 ◽  
Author(s):  
Julie Lecarpentier ◽  
Valentina Silvestri ◽  
Karoline B. Kuchenbaecker ◽  
Daniel Barrowdale ◽  
Joe Dennis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Cancer Susceptibility ◽  
Prostate Cancer Risk ◽  
Risk Scores ◽  
Cancer Risks ◽  
Prostate Cancer Susceptibility ◽  
Common Genetic Variants ◽  
Breast And Prostate Cancer ◽  
Male Carriers

Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated—for the first time to our knowledge—associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of BRCA1/2 mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. Results In male carriers of BRCA1/2 mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; P = 8.6 × 10−6). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; P = 3.2 × 10−9). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively. Conclusion PRSs may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.

Sign in / Sign up

Export Citation Format

Share Document